Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-3133-2026

MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201 Recall

MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201

FDA recall Class II

Ongoing

FDA lists this Class II recall for MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-3133-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Aug 5, 2026
FDA report date
Sep 16, 2026
Quantity in commerce
3,286 cases
Distribution
See key details
FDA cause
Process control

What is being recalled?

MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201

Affected model & UDI checker

Search the exact identifiers published for Z-3133-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
BC-100MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201Check source noticeNot specified
FDA code information

BC-100 - Lot:N4L022 (exp.11/13/2026), N4L037(exp.11/18/2026) BC+201- Lot: N4L010(exp.11/06/2026)

View the original FDA recall notice

Why was this product recalled?

Hemodialysis concentrates contain high endotoxin levels

What actions did Nipro Renal Soultions USA, Corporation take?

On August 6, 2026 Nipro Medical Corporation issued a Urgent Medical Device Recall notification via Email. Nipro asked consignees to take the following actions: 1. Immediately examine your inventory for the affected product codes and lot numbers listed on the Recall response form. 2. Immediately segregate, quarantine, and discontinue use or distribution of any affected product in your possession. 3. Do not use, sell, transfer, or distribute affected products. 4. Complete the enclosed Recall Response Form within 10 business days, even if you do not have affected product on hand. 5. Contact Nipro customer service for product return and credit, if applicable. 6. If you distributed affected product, promptly notify your customers, provide them with a copy of this recall notice, and request that they complete and return the response form or equivalent confirmation. 7. Product Return or Disposition: Affected products should remain quarantined until return, destruction, or other documented disposition instructions are provided by Nipro. Please retain all documentation related to product quarantine, return, destruction, or other disposition for recall reconciliation.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology